NanoPin Technologies


NanoPin has a diagnostic platform for infectious diseases that pulls targeted biomarkers directly from blood samples and greatly amplifies signal strength to rapidly detect and enable optimal treatment.  It is a powerful and versatile rapid response platform that will combat future contagions and will be initially commercialized in the tuberculosis (TB) diagnostic market, which will exceed $3 Billion by 2024 .  Unlike currently available tools, this technology provides quantified results that not only tells a patient if they have a disease, but how severe it is and how it changes over time and during treatment.